{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \\[%\\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\\*100.","groups":[{"description":"Pemetrexed 1910 milligrams per meters squared (mg/m\\^2) (or 60 milligrams per kilogram \\[mg/kg\\] if patient \\<12 months old)","id":"OG000","title":"Osteosarcoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG001","title":"Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG002","title":"Rhabdomyosarcoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG003","title":"Neuroblastoma (Measureable Disease)"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG004","title":"Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG005","title":"Ependymoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG006","title":"Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG007","title":"Non-Brainstem High-Grade Glioma"}],"paramType":"NUMBER","populationDescription":"All treated participants.","reportingStatus":"POSTED","timeFrame":"baseline to measured progressive disease (up to 1 year)","title":"Percentage of Participants With Overall Tumor Response (Response Rate)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}